3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
24
COCP Quote, Financials, Valuation and Earnings
Last price:
$1.42
Seasonality move
:
1.53%
Day range:
$1.38 - $1.46
52-week range:
$1.35 - $3.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.18x
P/B ratio:
1.14x
Volume:
19.6K
Avg. volume:
20.3K
1-year change:
1.43%
Market cap:
$14.4M
Revenue:
--
EPS (TTM):
-$1.85
Analysts' Opinion
-
Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.33, Cocrystal Pharma has an estimated upside of 486.85% from its current price of $1.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $1.42.
Fair Value
-
According to the consensus of 1 analyst, Cocrystal Pharma has 486.85% upside to fair value with a price target of $8.33 per share.
COCP vs. S&P 500
-
Over the past 5 trading days, Cocrystal Pharma has underperformed the S&P 500 by -8.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cocrystal Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cocrystal Pharma has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cocrystal Pharma reported revenues of --.
Earnings Growth
-
Cocrystal Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cocrystal Pharma reported earnings per share of -$0.49.
Enterprise value:
1.4M
EV / Invested capital:
--
Price / LTM sales:
7.18x
EV / EBIT:
--
EV / Revenue:
0.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$17.3M | -$20M | -$20.3M | -$6M | -$5M | |
| EBITDA | -$16.9M | -$19.6M | -$20M | -$5.9M | -$4.9M | |
| Diluted EPS | -$2.94 | -$2.00 | -$1.85 | -$0.41 | -$0.49 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.9M | $62.4M | $44.9M | $32.2M | $14.3M | |
| Total Assets | $53.2M | $82.6M | $45.6M | $32.6M | $16.2M | |
| Current Liabilities | $2.6M | $1.2M | $1.6M | $1.9M | $1.9M | |
| Total Liabilities | $3M | $1.6M | $1.7M | $1.9M | $3.5M | |
| Total Equity | $50.2M | $81M | $43.9M | $30.7M | $12.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.5M | -$16.2M | -$16.7M | -$2.7M | -$5.1M | |
| Cash From Investing | -$70K | -$71K | -$67K | -- | -- | |
| Cash From Financing | -$29K | $4M | -- | -- | -- | |
| Free Cash Flow | -$19.5M | -$16.3M | -$16.7M | -$2.7M | -$5.1M | |
COCP
Sector
Market Cap
$14.4M
$37M
Price % of 52-Week High
43.56%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
1.43%
-43.58%
Beta (5-Year)
2.215
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.50
200-day SMA
Sell
Level
$1.97
Bollinger Bands (100)
Sell
Level
1.65 - 2.25
Chaikin Money Flow
Sell
Level
-38.1M
20-day SMA
Sell
Level
$1.60
Relative Strength Index (RSI14)
Sell
Level
33.68
ADX Line
Sell
Level
12.84
Williams %R
Buy
Level
-89.7436
50-day SMA
Sell
Level
$1.80
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
72M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Stock Forecast FAQ
In the current month, COCP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The COCP average analyst price target in the past 3 months is $8.33.
-
Where Will Cocrystal Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cocrystal Pharma share price will rise to $8.33 per share over the next 12 months.
-
What Do Analysts Say About Cocrystal Pharma?
Analysts are divided on their view about Cocrystal Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cocrystal Pharma is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Cocrystal Pharma's Price Target?
The price target for Cocrystal Pharma over the next 1-year time period is forecast to be $8.33 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is COCP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cocrystal Pharma is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of COCP?
You can purchase shares of Cocrystal Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cocrystal Pharma shares.
-
What Is The Cocrystal Pharma Share Price Today?
Cocrystal Pharma was last trading at $1.42 per share. This represents the most recent stock quote for Cocrystal Pharma. Yesterday, Cocrystal Pharma closed at $1.42 per share.
-
How To Buy Cocrystal Pharma Stock Online?
In order to purchase Cocrystal Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 19.56% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 14.62% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 4.63% over the past day.
